07:00 , Oct 23, 2006 |  BC Week In Review  |  Clinical News

G4460: Phase I started

GNTA started a dose-escalation, U.S. Phase I trial in patients with hematologic cancers. The compound has Orphan Drug designation in the U.S. to treat chronic myelocytic leukemia (CML). Genta Inc. (GNTA), Berkeley Heights, N.J.   Product:...
07:00 , Aug 9, 2004 |  BC Week In Review  |  Company News

Inex other research news

Researchers published in the Journal of the National Cancer Institute that treatment with liposomal antisense oligonucleotides targeting c-myb increased long-term survival compared to a liposomal control oligonucleotide in a mouse model of neuroblastoma (p=0.009). Inex...